AACOMmunities

Federal Funding Opportunities and Resources

Below is a selected list of timely federal funding opportunities that are relevant to the osteopathic medical education community. AACOM updates this resource frequently.  Please bookmark the page for your reference. For a comprehensive listing of federal funding opportunities, please visit Grants.gov.   

The U.S. Department of Health and Human Services (HHS) has developed a Grant Opportunities and Guidance clearinghouse across all departments where you can find information about all aspects of the grant process during the COVID-19 crisis. For example, the NIH webpage provides  information and guidance about extensions, resubmissions, and funding opportunities related to COVID-19.  Its resources are also presented here, in a daily, updated format.

 

Featured Opportunities

 

Jan. 8 - 21, 2022

National Institutes of Health


Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)

Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)
Application Due Dates: February 25, 2022
The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions.

Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)
Application Due Dates:
March 15, 2022
The purpose of this program is to recruit and retain outstanding, postdoctoral-level health professionals who have demonstrated potential and interest in pursuing careers as clinician-investigators. To address the growing need for this critical component of the research workforce, this funding opportunity seeks applications from institutional programs that can provide outstanding mentored research opportunities for Resident-Investigators and foster their ability to transition to individual career development research awards.

HEAL Initiative: National K12 Clinical Pain Career Development Program (K12 Clinical Trial Not Allowed)
Letter of Intent Due Date(s):
30 days before application due date
Application Due Dates: March 24, 2022
The purpose of this FOA is to invite applications to the NIH HEAL Initiative’s Clinical Pain Career Development Program (HCPDP). The HCPDP supports the NIH HEAL Initiative’s long-term goals of providing effective non-opioid options for the treatment of pain by addressing the increased need for clinical pain researchers.

HEAL Initiative: Restoring Joint Health and Function to Reduce Pain Consortium (RE-JOIN) (UC2 Clinical Trial Not Allowed)
Letter of Intent Due Date(s):
March 11, 2022
Application Due Dates: April 11, 2022
The purpose of this Funding Opportunity Announcement is to solicit cooperative agreement applications from interdisciplinary teams that will cooperatively form the Restoring Joint Health and Function to Reduce Pain Consortium (RE-JOIN). The goal of RE-JOIN will be to define the innervation of the different articular and peri-articular tissues that collectively form the joint (including bone, cartilage, synovium, joint capsule, ligament, tendon, fascia and muscle), by sensory neurons that mediate the sensation of pain.

HEAL Initiative: Coordinating Center for National Pain Scientists Career Development (R24 Clinical Trial Not Allowed)
Letter of Intent Due Date(s):
30 days before application due date
Application Due Dates: March 24, 2022
This FOA invites applications for the Coordinating Center for National Pain Scientists (CCNPS). The CCNPS will be a central facilitator for integrating training and mentoring across a network of mentors and early-stage investigators funded by NIH (e.g., NIH trainees, NIH fellows, and Career Development Awardees).

HEAL Initiative: Advancing Health Equity in Pain and Comorbidities (R61/R33 Clinical Trial Required)
Letter of Intent Due Date(s): 30 days before application due date
Application Due Dates: March 22, 2022
The purpose of this FOA is to solicit applications to develop, test, and implement novel, culturally-appropriate pain interventions and/or adapt, test and evaluate efficacy and effectiveness of existing pain interventions, in populations that disproportionately experience negative health outcomes.

HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed)
Letter of Intent Due Date(s):
March 01, 2022
Application Due Dates: March 31, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to fund meritorious applications that analyze existing data and resources from humans, including large, diverse national research cohorts, to answer specific questions about the development of human acute or chronic pain and its management.

Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): 15 days before application due date
Application Due Dates: February 28, 2022
The Helping End Addiction Long-Term (HEAL) New Innovator Award supports a postdoctoral or newly independent Early Stage Investigator of exceptional creativity who proposes novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms, or advance key concepts on broad, important problems in biomedical research related to pain, opioid use disorder (OUD), and/or overdose (OD).

Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed)
Letter of Intent Due Date(s):
15 days before application due date
Application Due Dates: February 28, 2022
The purpose of this funding opportunity announcement (FOA) is to support early-stage research projects focusing on the identification of new druggable targets for pain, opioid use disorder and/or overdose within the understudied druggable proteome. This FOA is part of the NIH Helping to End Addiction Long Term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose.

Emergency Award HEAL Initiative: Optimizing Existing Evidence-Based Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional)

Emergency Award HEAL Initiative: Developing and Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional)

Letter of Intent Due Date(s):
February 18, 2022
Application Due Dates: March 18, 2022
The purpose of the initiative is to encourage research studies that will develop and optimize multi-component service delivery interventions that are un- or under-tested in people with opioid use disorder (OUD) and co-occurring conditions. Projects will examine the relative contribution of constituent components to overall effectiveness.

Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)
Letter of Intent Due Date(s): 15 days before application due date
Application Due Dates: February 28, 2022
This Funding Opportunity Announcement (FOA) invites applications from early and mid-career investigators (i.e. postdoctoral fellow/associates – associate professor) who strive to expand their research trajectories through the acquisition of new knowledge and skills in the areas of therapeutic drug, biologic, or device development.

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)

Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)

Letter of Intent Due Date(s):
30 days before application due date
Application Due Dates: March 04, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors and related disorders, prevention of substance use and HIV, and health service utilization.

NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)
Application Due Dates:
February 25, 2022
The purpose of the NIAID Career Transition Award program is to assist postdoctoral fellows' transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist.

Health Care Models for Persons with Multiple Chronic Conditions from Populations that Experience Health Disparities: Advancing Health Care towards Health Equity (R01 - Clinical Trials Optional)
Letter of Intent Due Date(s):
30 days before application due date
Application Due Dates: March 18, 2022
This initiative will support innovative, collaborative, and multi-disciplinary research designed to study the effective adaptation, integration, and implementation of recommended guidelines of care of persons with multiple chronic conditions (MCCs) from populations that experience health disparities.

Pilot Studies for the Spectrum of Alzheimer’s Disease/Alzheimer’s Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)
Application Due Dates:
March 04, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to invite research grant applications that enable the collection of pilot data to support early stage testing of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease.

Early and Late Stage Clinical Trials for the Spectrum of Alzheimer’s Disease/Alzheimer’s Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)
Application Due Dates:
March 04, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite applications that propose to develop and implement early to late stage clinical trials of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease.

Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)

Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)

Application Due Dates: February 16, 2022
The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes: Data Resource and Administrative Coordination Center (U24 Clinical Trial Not Allowed)

Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes: Assay and Data Generation Centers (RM1 Clinical Trial Not Allowed)

Letter of Intent Due Date(s):
30 days before application due date
Application Due Dates: June 10, 2022
This Funding Opportunity Announcement (FOA) is one of two to establish the Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes (SSPsyGene) Consortium. The long-term goal of SSPsyGene is to systematically characterize phenotypes, across biological scales of organization, for neurodevelopmental and psychiatric disorder (NPDs) risk genes.

Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 Clinical Trial Optional)
Letter of Intent Due Date(s):
February 28, 2022
Application Due Dates: March 28, 2022
The purpose of this initiative is support research to develop and test community-level interventions to improve minority health and reduce health disparities.

ARDS, Pneumonia, and Sepsis Phenotyping Consortium Coordinating Center (U01 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): May 17, 2022
Application Due Dates: June 17, 2022
This funding opportunity announcement (FOA) seeks applications for a Coordinating Center that will support the activities of a cooperative multi-site Acute Respiratory Distress Syndrome (ARDS), Pneumonia, and Sepsis Phenotyping Consortium (APS Consortium).

ARDS, Pneumonia, and Sepsis Phenotyping Consortium Clinical Centers (U01 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): May 17, 2022
Application Due Dates: June 17, 2022
This funding opportunity announcement (FOA) seeks applications for Clinical Centers to form a cooperative multi-site Acute Respiratory Distress Syndrome (ARDS), Pneumonia, and Sepsis Phenotyping Consortium (APS Consortium).

Advancing Research on Mechanisms and Management of Pain for Diseases and Conditions within NIDDK Mission Areas (R01 Clinical Trial Optional)
Letter of Intent Due Date(s):
April 17, 2022
Application Due Dates: May 17, 2022
The current Funding Opportunity Announcement will address these needs through the invitation of broad investigator-initiated research projects proposing novel basic, translational, and clinical studies and efforts to develop new approaches to assess and treat pain for disorders within the NIDDK's mission. Investigations are expected to provide important new insights into the pathophysiology and clinical features of pain and foster new and improved treatment and pain management strategies for patients.

Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)
Letter of Intent Due Date(s):
30 days before application due date
Application Due Dates: June 05, 2022
This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research.

Community Engaged Research on Pregnancy Related and Associated Infections and Sepsis Morbidity and Mortality (UG3/UH3 Clinical Trial Optional)
Letter of Intent Due Date(s):
30 days before application due date
Application Due Dates: April 18, 2022
The purpose of this FOA is to support interdisciplinary community-engaged research designed to reduce or eliminate infections and sepsis as causes of pregnancy- related or associated morbidity and mortality (PRAMM) in the United States. This FOA is to support research primarily focused on PRAMM health disparities in areas with highest maternal morbidity and mortality.

Revolutionizing Innovative, Visionary Environmental Health Research (RIVER) (R35 Clinical Trial Optional)
Letter of Intent Due Date(s):
30 days before application due date
Application Due Dates: June 09, 2022
The NIEHS Revolutionizing Innovative, Visionary Environmental health Research (RIVER) program is intended to provide support for outstanding investigators in the Environmental Health Sciences, giving them intellectual and administrative freedom, as well as sustained support to pursue their research in novel directions in order to achieve greater impacts.

Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)

Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)
Application Due Dates:
June 05, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

Health Resources and Services Administration

Rural Communities Opioid Response Program – Behavioral Health Care Support
Application Due Dates:
April 19, 2022
The Rural Communities Opioid Response Program (RCORP) is a multi-year initiative by the Health Resources and Services Administration (HRSA) aimed at reducing the morbidity and mortality of substance use disorder (SUD), including opioid use disorder (OUD), in high risk rural communities. The purpose of this program is to advance RCORP’s overall goal by improving access to and quality of SUD and other behavioral health care services in rural communities.

 

Dec.11, 2021 - Jan. 7, 2022

Health Resources and Services Administration

Rural Maternity and Obstetrics Management Strategies Program
Application Due Dates: April 05, 2022
This notice announces the opportunity to apply for funding under the Health Resources and Services Administration’s (HRSA) Rural Maternity and Obstetrics Management Strategies (RMOMS) program. The purpose of the RMOMS program is to improve access to and continuity of maternal and obstetrics care in rural communities.

Area Health Education Centers Program
Application Due Dates: April 06, 2022
The purpose of the AHEC Program is to develop and enhance education and training networks within communities, academic institutions, and community-based organizations. In turn, these networks seek to increase diversity among health professionals, broaden the distribution of the health workforce, enhance health care quality, and improve health care delivery to rural and underserved areas and populations.

National Institutes of Health

Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)
Letter of Intent Due Date(s): 15 days prior to the application due date
Application Due Dates: February 18, 2022
This Funding Opportunity Announcement (FOA) invites applications from early and mid-career investigators (i.e. postdoctoral fellow/associates – associate professor) who strive to expand their research trajectories through the acquisition of new knowledge and skills in the areas of therapeutic drug, biologic, or device development. The development of novel treatments for pain, addiction, and overdose is a vital component to address the ongoing opioid epidemic.

Physician Scientist Transition to Independence in Blood Science Research (R00 - Clinical Trial Optional)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: March 28, 2022
The purpose of the NHLBI Career Pathway to Independence in Blood Science Award for Physician Scientists (R00) is to increase and maintain a strong cohort of new and talented, NHLBI supported, independent investigators in blood science. This program is designed to facilitate a timely transition of outstanding blood science researchers with a clinical doctorate degree from mentored research positions to independent, tenure-track or equivalent faculty positions.

Maintaining and Enriching Environmental Epidemiology Cohorts to Support Scientific and Workforce Diversity (U24 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: March 08, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to: (1) support the maintenance and resource infrastructure enrichment of existing Environmental Epidemiology Cohorts (EECs) and to (2) enrich data management and data sharing activities to promote widespread data sharing and scientific collaborations, while strengthening scientific and workforce diversity in environmental health.

Risk and Protective Factors of Family Health and Family Level Interventions (R01 - Clinical Trial Optional)
Application Due Dates: June 05, 2022
The purpose of this initiative is to advance the science of minority health and health disparities by supporting research on family health and well-being and resilience. The NIMHD Research Framework recognizes family health, family well-being, and family resilience as critically important areas of research to decrease disparities and promote equity.

SPARC VNS Endpoints from Standardized Parameters (VESPA) (U54 Clinical Trial Required)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: April 01, 2022
The purpose of this Funding Opportunity Announcement is to solicit applications for a U54 Research Center to conduct a large multisite clinical study of the multi-organ effects of vagus nerve stimulation (VNS) in response to a standardized range of VNS parameters in humans. These data will be shared publicly and inform the optimization of VNS treatment by providing the broad functional impact on systems physiology and elucidate the functional connectivity of the human vagus nerve.

NIH-DOD-VA Pain Management Collaboratory – Pragmatic and/or Implementation Science Demonstration Projects ((UG3/UH3) Clinical Trial Required)
Letter of Intent Due Date(s): February 15, 2022
Application Due Dates: March 15, 2022
The purpose of this FOA is to solicit UG3/UH3 phased cooperative agreement research applications to conduct efficient, large-scale pragmatic clinical trial and/or implementation science Demonstration Projects within the infrastructure of the NIH-DOD-VA Pain Management Collaboratory (PMC) on nonpharmacologic approaches to pain management and other comorbid conditions in U.S. military personnel, veterans and their families.

Center for Rapid Surveillance of Tobacco (CRST) to Assess Changes in Use Behaviors, Product Marketing, and the Marketplace (U01 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): March 20, 2022
Application Due Dates: May 18, 2022
This Funding Opportunity Announcement (FOA) solicits applications for a Center for Rapid Surveillance of Tobacco (CRST) to assess changes in use behaviors, product marketing, and the marketplace to better understand the rapidly evolving tobacco landscape in the United States. The CRST will support time-sensitive data acquisition strategies, data harmonization, data synthesis and analysis, and reporting activities on emerging and current tobacco use.

Resources to Promote Coordination and Collaboration across Deeply Phenotyped Longitudinal Behavioral and Social Studies of Aging (U24 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): February 01, 2022
Application Due Dates: March 03, 2022
This Funding Opportunity Announcement (FOA) invites applications to establish a Resource Development Network focused on the infrastructure needed to promote and support coordination, collaboration, and innovation across deeply phenotyped longitudinal behavioral and social studies of aging that are rich in psychological, behavioral, and biobehavioral content.

HEAL Initiative: Exploratory Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R21- Clinical Trial Not Allowed)

HEAL Initiative: Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R01- Clinical Trial Not Allowed)
Application Due Dates: March 10, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to develop new methods, approaches, and/or tools to apply to existing data streams (e.g., electronic health records, syndromic surveillance, claims data, registry data, pharmacy dispensing, and mortality records) that could provide novel insights into the dynamics of opioid and prescription drugs misuse, addiction, recovery, relapse, and recovery to facilitate rapid understanding of the opioid epidemic for prevention and treatment or to develop methods for small area estimation that inform decisions of local (e.g., substate) jurisdictions.

Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: June 03, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications from single institutions or consortia of institutions to participate in the Asthma and Allergic Diseases Cooperative Research Centers (AADCRC) program.

Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
Application Due Dates: June 05, 2022
The Stimulating Hematology Investigation:  New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI).

Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)

Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
Application Due Dates: March 11, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing new tests, animal models, techniques, etc. to advance research on Alzheimer's disease (AD) and its related dementias (ADRD) that need additional preliminary data with broader dissemination to establish them for more general use in this research field.

Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional)

Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: March 15, 2022
The purpose of this FOA is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental.

Lipids in Brain Aging and Alzheimer's Disease (AD) and its Related Dementias (ADRD) (R01 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): May 15, 2022
Application Due Dates: June 14, 2022
The goal of this Funding Opportunity Announcement (FOA) is to support research addressing critical knowledge gaps in our understanding of how lipids contribute to vulnerability and resilience to brain aging and Alzheimer’s disease (AD) and its related dementias (ADRD).

HEAL Initiative: Understanding Polysubstance Use and Improving Service Delivery to Address Polysubstance Use (R01 Clinical Trial Optional)
Letter of Intent Due Date(s): February 10, 2022
Application Due Dates: March 10, 2022
The purpose of this FOA is to support R01-level projects that will address polysubstance use involving opioids and stimulants that can contribute to 1) understanding of the dynamics of polysubstance use, 2) improving outcome measurement in the context of polysubstance use, 3) personalizing preventative and treatment services approaches in the context of polysubstance use.

HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional)

HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders: Coordination Center (R24 Clinical Trial Optional)
Letter of Intent Due Date(s): February 10, 2022
Application Due Dates: March 10, 2022
The National Institutes of Health (NIH) intends to establish a Harm Reduction Network consisting of several research projects, which will be supported by a single Coordination Center. The goal of this network is to increase our understanding of the effectiveness, implementation, and impact of existing and new harm reduction practices to address the ongoing opioid crisis and substance use disorder more broadly. This FOA seeks applications for a single Coordination Center for the Harm Reduction network.

HEAL Initiative: Pilot & Feasibility Trials to Improve Prevention and Treatment Service Delivery for Polysubstance Use (R34 Clinical Trial Optional)
Letter of Intent Due Date(s): February 10, 2022
Application Due Dates: March 10, 2022
The purpose of this FOA is to encourage pilot and preliminary research in preparation for larger-scale services research effectiveness trials focused on personalized treatment and prevention services approaches to address polysubstance use.

HEAL Initiative: Research Networks for the Study of Recovery Support Services for Persons Treated with Medications for Opioid Use Disorder (R24 Clinical Trial Optional)
Letter of Intent Due Date(s): February 10, 2022
Application Due Dates: March 10, 2022
This Funding Opportunity Announcement (FOA) is to support applications providing infrastructure support to advance the development of efficacy and/or effectiveness research on recovery support services for those who take or have taken medications for the treatment of opioid use disorder (MOUDs).

HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: March 02, 2022
The focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability.

Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)

Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)

Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)

Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional)

Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional)

Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: April 22, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program.

HEAL Initiative: HEAL Data2Action (HD2A) Data Infrastructure Support Center (U24 Clinical Trial Optional)
Letter of Intent Due Date(s): February 10, 2022
Application Due Dates: March 10, 2022
This FOA seeks applications for one HEAL D2A Data Infrastructure Support Center (DISC) to provide support for the HEAL D2A Innovation Projects. The Center’s primary purpose is to facilitate the compilation and use of data by local communities and health systems to identify trends and service delivery gaps, and to monitor improvements, related to substance use, pain management, and reduction of overdose outcomes.

HEAL Initiative: HEAL Data2Action Innovation Projects (R61/R33 Clinical Trial Optional)
Letter of Intent Due Date(s): February 10, 2022
Application Due Dates: March 10, 2022
This FOA solicits applications for HEAL D2A Innovation Projects, which are phased awards intended to support local efforts, either within a single system or in cross-sector partnerships, to improve utilization of data to drive prediction and real-time proactive responses to the overdose crisis.

HEAL Initiative: HEAL Data2Action Modeling and Economic Resource Center (U24 Clinical Trial Optional)
Letter of Intent Due Date(s): February 10, 2022
Application Due Dates: March 10, 2022
This FOA seeks applications for one HEAL D2A Modeling and Economic Resource Center to support the HD2A Innovation Projects. This center will provide expertise in a variety of simulation modeling and economic analyses and methods and will consult with the HD2A Innovation Grants on applying these methods and insights in their local implementation activities.

HEAL Initiative: HEAL Data2Action Research Adoption Support Center (U2C Clinical Trial Optional)
Letter of Intent Due Date(s): February 25, 2022
Application Due Dates: March 25, 2022
This FOA seeks applications for one HEAL D2A Research Adoption Support Center to provide coordination and implementation support for the HEAL D2A Innovation Projects. The Center’s primary purpose is to support funded projects in the selection and adoption of evidence-based practices to address specific service delivery gaps in the areas of substance use prevention and treatment and pain management

Advancing communication strategies to support future HIV vaccine use (R01 Clinical Trial Optional)

Advancing communication strategies to support future HIV vaccine use (R21 Clinical Trial Optional)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: May 10, 2022
This Funding Opportunity Announcement (FOA) invites applications for Research Project Grants that will advance novel health communication research designed to inform and support acceptance and uptake of future vaccines that protect against HIV.

Biomedical Research Facilities (C06 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): February 15, 2022
Application Due Dates: March 15, 2022
This Funding Opportunity Announcement (FOA) invites qualified academic and research institutions to apply for funding to modernize existing or construct new biomedical research facilities. Applications will be accepted from public and private nonprofit institutions of higher education as well as from non-profit research organizations. Applications from both research-intensive institutions and Institutions of Emerging Excellence in biomedical research from all geographic regions in the nation are strongly encouraged.

Elucidating the heterogeneity of impaired awareness of hypoglycemia in Type 1 Diabetes (T1D) Clinical Centers (U01 Clinical Trial Required)
Letter of Intent Due Date(s): March 01, 2022
Application Due Dates: March 31, 2022
The purpose of this FOA is to establish a clinical consortium to determine the factors that contribute to the heterogeneity in the restoration of impaired awareness of hypoglycemia (IAH) and improved counter-regulatory responses in adult individuals with Type 1 Diabetes (T1D).

Elucidating the heterogeneity of impaired awareness of hypoglycemia in Type 1 Diabetes (T1D) - Biostatistics Research Center (U01 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): March 01, 2022
Application Due Dates: March 31, 2022
This FOA invites applications for a Biostatistics Research Center (BRC) to participate in a clinical consortium to determine the factors that contribute to the heterogeneity in the restoration of impaired awareness of hypoglycemia (IAH) and improved counter-regulatory responses in adult individuals with Type 1 Diabetes (T1D) and impaired awareness of hypoglycemia (IAH).

Pharmacokinetic and Pharmacodynamic (PK/PD) Studies of mTOR Inhibitors on Aging-Related Indications (U01 Clinical Trial Required)
Letter of Intent Due Date(s): April 14, 2022
Application Due Dates: May 14, 2022
This Funding Opportunity Announcement (FOA) invites applications for pharmacokinetic and pharmacodynamic (PK/PD) studies of mTOR inhibitors in populations living with different aging-related diseases or in relatively healthy older adult populations at risk for a variety of aging conditions.

Coordinating Center for the Claude D. Pepper Older Americans Independence Centers (OAICs) (U24 Clinical Trial Optional)
Letter of Intent Due Date(s): April 16, 2022
Application Due Dates: May 16, 2022
The National Institute on Aging (NIA) seeks applications for the Coordinating Center (CC) of the Claude D. Pepper Older Americans Independence Centers (OAIC) program. The CC serves as a facilitator for OAIC site interactions and as a conduit for translating OAIC objectives and findings to both scientific and general audiences.

Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies For Acute Cerebroprotection- Interventions (U01 Clinical Trial Not Allowed)

Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Cerebroprotection - Testing Laboratories (U01 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: March 14, 2022
The purpose of this funding opportunity announcement (FOA) is to invite applications for testing laboratories to take part in the NINDS Stroke Preclinical Assessment Network (SPAN). SPAN will facilitate the testing of up to 8 promising cerebroprotective drugs or interventions to be given prior to or at the time of reperfusion in experimental models of ischemic.

Limited Competition: Basic Instrumentation Grant (BIG) Program (S10 Clinical Trial Not Allowed)
Application Due Dates: June 01, 2022
The Basic Instrumentation Grant (BIG) Program encourages applications from groups of NIH-supported investigators to purchase a single high-priced, specialized, commercially available instrument or an integrated instrumentation system. The minimum award is $25,000. There is no maximum price limit for the instrument; however, the maximum award is $250,000.

Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed)
Application Due Dates: June 01, 2022
The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially available instruments or integrated instrumentation system. The minimum award is $50,000. There is no maximum price limit for the instrument; however, the maximum award is $600,000.

High-End Instrumentation (HEI) Grant Program (S10 Clinical Trial Not Allowed)
Application Due Dates: June 01, 2022
The High-End Instrumentation (HEI) Grant Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially available instruments or integrated systems. The minimum award is $600,001. There is no maximum price limit for the instrument; however, the maximum award is $2,000,000.

NIA Renewal and Competing Revision Cooperative Agreements in Aging Research (U01 Clinical Trial Optional)
Application Due Dates: March 01, 2022
This Funding Opportunity Announcement (FOA) allows for renewal and competing revision applications, and their resubmissions, for awarded U01 research project cooperative agreements focused on aging research.

Host Immunity and Novel Immunization Strategies for Clostridioides difficile Infection (CDI) (U19 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: May 20, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to support the formation of Cooperative Research Centers (CRCs) to pursue vaccine development through multidisciplinary investigations into the host immune response to Clostridioides difficile infection (CDI).

Centers for Disease Control and Prevention

Research Grants to Evaluate the Effectiveness of Physical Therapy-based Exercises and Movements Used to Reduce Older Adults Falls (U01)
Letter of Intent Due Date(s): January 14, 2022
Application Due Dates: March 01, 2022
The Centers for Disease Control and Prevention's National Center for Injury Prevention and Control (NCIPC) is soliciting investigator-initiated research proposals to support both a process evaluation and an outcome evaluation of the effectiveness of strategies (different types of physical therapy-based exercises and movements, such as heel-to-toe walk, sit-to-stand exercise, calf raises, side leg raise) commonly used to improve community-dwelling older adults' balance and mobility and subsequently reduce their risk of future falls and fall injuries.

Rigorous Evaluation of Strategies to Prevent Overdose through Linking People with Illicit Substance Use Disorders to Recovery Support Services
Letter of Intent Due Date(s): January 17, 2022
Application Due Dates: March 14, 2022
The Centers for Disease Control and Prevention (CDC) National Center for Injury Prevention and Control (NCIPC) is soliciting investigator-initiated research that will support the identification and rigorous evaluation of effective strategies that link people in recovery for illicit substance use disorders to at least one evidence-based recovery support service available within their community, and, if needed, re-link people to such services following resumption of illicit substance use.